Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2025 Feb 6;209:104627. doi: 10.1016/j.critrevonc.2025.104627.
2025
AOU San Luigi di Orbassano
ASL Torino 3
ASL Asti
AOU San Luigi di Orbassano
ASL Torino 3
ASL Asti
Tipo pubblicazione
Review
Autori/Collaboratori (8)Vedi tutti...
Colombo C
Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
De Leo S
Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Campisi I
Department of Oncology, University of Turin, Turin, Italy.
et alii...
Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
De Leo S
Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Campisi I
Department of Oncology, University of Turin, Turin, Italy.
et alii...
Abstract
Nowadays immune-based combinations are the standard first-line treatment for metastatic renal cell carcinoma and involve the use of either two immunotherapy agents or an immunotherapeutic drug associated with a tyrosine kinase inhibitor. Treatment-related toxicity is the primary cause of drug discontinuation or dose reduction. A thorough understanding of the prevention and management of adverse events of the immune-based combinations is critical to ensure the success of treatment. Endocrinological toxicities during treatment with immune-based combinations are frequent and often manageable. However, in some cases, diagnosis can be complex, and the treatment requires multidisciplinary discussion. In addition, it is often challenging to determine which agent in the combination is responsible for a specific toxicity. In this review, we analyze the evidence regarding treatment-related endocrinopathies in renal cell carcinoma first-line therapy. We also discuss monitoring strategies to diagnose endocrinological adverse events and provide some practical tools for their daily management.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.
PMID : 39922397
DOI : 10.1016/j.critrevonc.2025.104627
Keywords
Antiangiogenic therapies; Endocrinological adverse events; Immunotherapy; Management; Renal cell carcinoma; Toxicities;